A unit of Fosun International (HKG:0656) agreed to purchase 14,940,694 unlisted shares in Shanghai Henlius Biotech (HKG:2696) from HenLink for a little over HK$367.5 million, a Monday filing with the Hong Kong bourse said.
Shanghai Fosun Pharmaceutical Industrial Development will purchase the shares at HK$24.60 apiece.
The buyer had, in two previous transactions this month, acquired a total of 6,093,619 shares in pharmaceutical firm Henlius Biotech.
Following the completion of all three transactions, conglomerate Fosun International will hold 63.43% of Henlius Biotech's total issued share capital.